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Background: Bone marrow-derived circulating progenitor cells (BM-CPCs) in patients with coronary heart disease
are impaired with respect to number and functional activity. However, the relation between the functional activity
of BM-CPCs and the number of diseased coronary arteries is yet not known. We analyzed the influence of the
number of diseased coronary arteries on the functional activity of BM-CPCs in peripheral blood (PB) in patients with
ischemic heart disease (IHD).
Methods: The functional activity of BM-CPCs was measured by migration assay and colony forming unit in 120
patients with coronary 1 vessel (IHD1, n = 40), coronary 2 vessel (IHD2, n = 40), coronary 3 vessel disease (IHD3,
n = 40) and in a control group of healthy subjects (n = 40). There was no significant difference of the total number
of cardiovascular risk factors between IHD groups, beside diabetes mellitus (DM), which was significantly higher in
IHD3 group compared to IHD2 and IHD1.
Results: The colony-forming capacity (CFU-E: p< 0.001, CFU-GM: p< 0.001) and migratory response to stromal cell-
derived factor 1 (SDF-1: p< 0.001) as well as vascular endothelial growth factor (VEGF: p< 0001) of BM-CPCs were
reduced in the group of patients with IHD compared to control group. The functional activity of BM-CPCs was
significantly impaired in patients with IHD3 as compared to IHD1 (VEGF: p< 0.01, SDF-1: p< 0.001; CFU-E: p< 0.001,
CFU-GM: p< 0.001) and to IHD2 (VEGF: p = 0.003, SDF-1: p = 0.003; CFU-E: p = 0.001, CFU-GM: p = 0.001). No
significant differences were observed in functional activity of BM-CPCs between patients with IHD2 and IHD1 (VEGF:
p = 0.8, SDF-1: p = 0.9; CFU-E: p = 0.1, CFU-GM: p = 0.1). Interestingly, the levels of haemoglobin AIc (HbAIc)
correlated inversely with the functional activity of BM-CPCs (VEGF: p< 0.001, r =−0.8 SDF-1: p< 0.001, r =−0.8; CFU-
E: p = 0.001, r =−0.7, CFU-GM: p = 0.001, r =−0.6) in IHD patients with DM.
Conclusions: The functional activity of BM-CPCs in PB is impaired in patients with IHD. This impairment increases
with the number of diseased coronary arteries. Moreover, the regenerative capacity of BM-CPCs in ischemic tissue
further declines in IHD patients with DM. Furthermore, monitoring the level of BM-CPCs in PB may provide new
insights in patients with IHD.
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Circulating progenitor cells (CPCs) are primitive bone
marrow cells (BMCs), that have the capacity to prolifer-
ate, migrate, and differentiate into various mature cell
types. [1-3] Furthermore, these cells circulate in periph-
eral blood, and implicate in neoangiogenesis after tissue
ischemia. [4-6] Experimental studies have shown that re-
introduction of cytokines such as vascular endothelial
growth factor (VEGF), angiopoetin-1, SDF-1, G-CSF, or
GM-CSF enhance the mobilization of the BM-CPCs to
the ischemic myocardium, augmenting neovasculariza-
tion. [7,8] It has been suggested that cardiovascular risk
factors (CVRFs) are associated with reduction of func-
tional activity of BM-CPCs in patients with coronary ar-
tery disease as well as in healthy men. [9,10] Moreover,
especially diabetes has been shown to reduce numbers
and impair functional activity of BM-CPCs. [11-13]
However, it is unknown whether the functional activity
of BM-CPCs relates to the number of diseased coronary
arteries in patients with IHD. In this study, we analyzed
the functional activity of BM-CPCs and their relation-
ship with the number of diseased coronary arteries in
IHD-patients.
Methods
Study protocol and study population
132 IHD patients between 18–80 years of age were
screened for inclusion in this study, if they had had a
documented MI at least 6 months ago and had left ven-
tricular dysfunction. 12 of 132 patients had to be
excluded from the study due to acute coronary syndrom
and/or acutely decompensated heart failure. All 120 IHD
patients underwent diagnostic cardiac catheterization
due to stable angina. We selected a control group of 40
healthy subjects without overt heart disease and/or
major cardiovascular risk factors such as diabetes, smok-
ing, hypertension, hypercholesterolemia, and positive
family history concerning IHD. All of them had atypical
chestpain but no evidence of cardiac ischaemia. Control
subjects underwent coronary angiography to rule out is-
chaemic heart disease within 24 hours after admission.
The patients were recruited during diagnostic cardiac
catheterization by interventional cardiologist and were
separated into 4 groups (I) IHD1; II) IHD2; III) IHD3
and IV) Control group). After this step a peripheral
blood sample was taken during cardiac catheterization
to measure functional activity and characterization of
BM-CPCs before any interventional procedure. A
CVRFs score including age> 40 years, male sex, hyper-
tension, diabetes, smoking, positive family history and
hypercholesterolaemia was calculated according to Vita
et al. [14] Hypertension was defined as a history of
hypertension for >1 year that required the initiation of
antihypertensive therapy by the primary physician.Smoking was defined as patients revealing a history of
smoking for >2 pack-years and current smoking. Posi-
tive family history was defined as documented evidence
of coronary artery disease (CAD) in a parent or sibling
before 60 years of age. Hypercholesterolaemia was
defined as fasting low-density-lipoprotein (LDL) choles-
terol levels exceeding 130 mg/dl. Diabetes was defined
as the need for oral antidiabetic drug therapy or insulin
use.
Exclusion criteria were the presence of acutely decom-
pensated heart failure with a New York Heart Associ-
ation (NYHA) class of IV, infectious or inflammatory
disease, surgery or trauma within 2 months, renal or
liver dysfunction, thrombocytopenia, anemia, severe
comorbidity and alcohol or drug dependency, history of
other severe chronic diseases or cancer, or unwillingness
to participate. The study conforms with the principles
outlined in the Declaration of Helsinki and was
approved by the local ethics committee. Written
informed consent was obtained from each patient.
Coronary angiography and left ventriculography
All IHD patients underwent left heart catheterization,
left ventriculography and coronary angiography. Cardiac
catheterization was performed according to the guide-
lines for coronary angiography of the American College
of Cardiology and the American Heart Association. [15]
Cardiac function was determined by left ventriculogra-
phy. Cardiac function was evaluated by global EF. Global
EF was measured with Quantcor software (Siemens,
Erlangen/Germany). The extent of coronary artery dis-
ease was scored, by at least two independent interven-
tional cardiologists, as 0 (stenosis< 50 percent), 1
(stenosis of any main coronary artery> 50 percent), 2
(stenosis of two main coronary arteries> 50 percent),
and 3 (stenosis of three main coronary arteries> 50
percent).
Phenotypic characterization of BM-CPCs
Phenotypic characterization of BM-CPCs were per-
formed in 5 of 20 ml peripheral blood (PB) for CD34/45
+ and CD133/45+ by flow cytometry (EPICS-XL, Beck-
mann Coulter).
Samples were stained with fluorescein isothiacyanate
(FITC) conjugate of a CD45+ antibody (clone J33,
Coulter/Immunotech, Marseille/France) that detects all
isoforms and glycoforms of the CD45 family, phyco-
erythrin (PE) conjugate of a CD34+ antibody (clone 581,
Coulter/Immunotech, Marseille/France) that detects a
class III epitope on all glycoforms of the CD34+ antigen
and PE conjugate of a CD133/1+ (Miltenyi Biotec, Ber-
gisch Gladbach/Germany). Control samples were stained
with CD45+ FITC and an IgG1 PE (Coulter/Immuno-
tech, Marseille/France) isotype.











Age 60 ± 15 60 ± 11 64 ± 10 NS 66 ± 10
male 24 26 25 NS 21
Cardiovascular Risk Factors % (n)
Hypertension 80 (n = 32)80 (n = 32)78 (n = 31) NS -
Hyperlipidemia 60 (n = 24)60 (n = 24)53 (n = 21) NS -
Smoking 68 (n = 27)75 (n = 30)63 (n = 25) NS -
Positive family
history of CAD
40 (16) 40 (n = 16)35 (n = 14) NS -
Diabetes 20 (n = 8) 20 (n = 8) 60 (n = 24)p = 0.001 -
OHA 15 (n = 6) 15 (n = 6) 45 (n = 18) NS -
Insulin 5 (n = 2) 5 (n = 2) 15 (n = 6) NS -
Total number of CVRFs 4.2 ± 0.8 4.3 ± 0.8 4.4 ± 0.9 NS -
Infarct-related vessel
(LAD/LCX/RCA)
19/8/13 20/10/11 20/8/12 NS -
PTCA/Stent at the
time of AMI
40/40 40/40 40/40 NS -
Ejection fraction (%) 45 ± 10 43 ± 11 40 ± 10 NS 69 ± 9
Medication (%) -
Aspirin 100 100 100 NS -
Clopidogrel 100 100 100 NS -
ACE inhibitor or
AT II blocker
100 100 100 NS -
Beta-blocker 100 100 100 NS -
Aldosterone Antagonist 25 25 30 NS -
Statin 100 100 100 NS -
Ischemic heart disease (IHD), Oral hypoglycaemic agent (OHA), Coronary artery
disease (CAD), Percutaneous transluminal coronary angioplasty (PTCA),
Creatine kinase (CK), Left anterior descending coronary artery (LAD), Left
circumflex artery (LCX), Right coronary artery (RCA), Coronary artery disease
(CAD), Cardiovascular risk factors (CVRFs), Acute myocardial infarction (AMI),
None significant (NS).
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with CD34/45+, CD133/45+, and IgG1/CD45. All tubes
were incubated at room temperature in the dark. After
incubation, cells were lysed with ammonium chloride,
washed with phosphate-buffered saline (PBS). Samples
were then stored on ice at 4 °C in dark environment for
20 minutes and analysed by flow cytometry.
Samples were subjected to a 2D side scatter-
fluorescence dot plot analysis. After appropriate gating,
the concentration of BM-CPCs with low cytoplasmic
granularity (low side ward scatter) was quantified and
expressed as concentration of cells per million white
blood cells.
Isolation and cultivation of BM-CPCs
20 ml peripheral venous blood was taken using a BD
Vacutainer CPTTM from each patient. BM-CPCs were
isolated by density gradient centrifugation. After 2 wash-
ing steps, cells were resuspended in 1 ml EBM2-medium
(Cell system). The number of isolated BM-CPCs were
determined in a Neubauer chamber.[10,16]
Assessment of migration assay
A total of 1x106 BM-CPCs were resuspended in 250 μl X-
Vivo and placed in the top compartment of a Boyden
Chamber. This chamber was placed in a 24-well culture
dish contained either only EBM-2 medium or 100 ng/ml
stromal cell derived factor-1 (SDF-1) or 100 ng/ml vascu-
lar endothelial growth factor (VEGF) in EBM2-medium.
After 24 hours of incubation at 37 °C transmigrated cells
were counted by 2 independent investigators. [10,16]
Quantitative evaluation of migrated cells to SDF-1 and
VEGF were analyzed in comparison to cells without che-
mokine in blood samples of both groups. Values are
expressed as % of migrated cells without chemokine.
Assessment of colony forming unit assay
1x105 in BM-CPCs per ml were seeded in Methocult GF
H4435 (Stemcell Technologies). Culture dishes were
seeded with 1 ml cell suspension and then incubated at
37 °C. Colony-forming unit erythroid (CFU-E) and CFU-
granulocyte/macrophage (CFU-GM) were studied under
phase-contrast microscopy and were counted after 14 days
of incubation by 2 independent investigators. [16]
Biochemical measurements
Peripheral blood was collected from patients with IHD
and control group on day 1 of admission. Serum creatine
phosphokinase (CPK) values (normal range: 24–195 U/
l), inflammatory markers such as C - reactive protein
(normal range <0.5 mg/dl) and leukocytes (normal
range: 4–12 x103/μl) and routine laboratory tests with
HbA1C were measured in the study population.Statistical analysis
Continuous data are presented as mean ± SD. Compari-
son of the distributions of a continuous variable between
two independent groups was performed using the two-
sided nonparametric Mann–Whitney test. The type I
error rate α was chosen as 5% and two-sided p-values
equal or less 0.05 were interpreted as statistically signifi-
cant. Some qualitative baseline characteristics were com-
pared using the Fisher's Exact-Test.
Bivariate regression analysis was presented in a graphical
form and Pearson's correlation coefficient was obtained.
Statistical significant was accepted, if the correspond-
ing two-sided p-value was smaller or equal to 0.05. Stat-
istical analysis was performed with SPSS for Windows
(Version 15.0).
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Baseline characteristics of the patients and healthy
control subjects
We included 120 patients with IHD and 40 healthy sub-
jects without heart disease in the study. The baseline char-
acteristics of the study population are depicted in Table 1.
Although there was no significant difference in total num-
ber of CVRFs between all IHD patients groups, interest-
ingly, there was a significant difference in the number of
DM patients in IHD3 group compared to IHD1 and
IHD2. In contrast, there was no significant difference in
the number of DM patients between IHD1 and IHD2.
Also no significant differences were observed in other
baseline characteristics and demographics of patients be-
tween all IHD groups. No significant differences were
observed in age and sex between all groups (Table 1).
Functional activity of BM-CPCs
The functional capacities of BM-CPCs were measured
by migratory- and colony forming assay in 120 IHD
patients as well as in 40 healthy subjects on day 1 of ad-
mission. The migratory response to stromal cell-derivedFigure 1 A and B: The colony-forming capacity and migratory respon
growth factor of BM-CPCs were reduced in patients with IHD comparfactor 1 (SDF-1: p< 0.001) as well as vascular endothe-
lial growth factor (VEGF: p< 0001) of BM-CPCs was
impaired in patients with IHD compared to control
group. Likewise, the colony-forming capacity (CFU-E: p
< 0.001, CFU-GM: p< 0.001) was reduced in patients
with IHD compared to control group. (Figure 1A and
1B) Furthermore, we found that the migratory -and col-
ony forming capacities of BM-CPCs were significantly
impaired in patients with IHD3 compared to IHD1
(VEGF: p< 0.001, SDF-1: p< 0.001; CFU-E: p< 0.001,
CFU-GM: p< 0.001) and to IHD2 (VEGF: p = 0.003,
SDF-1: p = 0.003; CFU-E: p = 0.001, CFU-GM: p = 0.001).
In contrast, there were no significant differences in the
functional activity of BM-CPCs between the patients
with IHD2 and IHD1 (VEGF: p = 0.8, SDF-1: p = 0.9;
CFU-E: p = 0.1, CFU-GM: p = 0.1). (Figure 2A and 2B)
Impact of DM on the functional activity of BM-CPCs in
patients with IHD
We investigated the correlation between DM (n= 40)
and functional activity of BM-CPCs in patients with
IHD. We observed a significant inverse correlationse to stromal cell-derived factor 1 as well as vascular endothelial
ed to control group.
Figure 2 A and B: The migratory -and colony forming capacities of BM-CPCs were significantly impaired in patients with IHD3
compared to IHD1 and IHD2. In contrast, there were no significant changes in functional activity of BM-CPCs between the patients with IHD2
and IHD1.
Bozdag-Turan et al. Journal of Translational Medicine 2012, 10:143 Page 5 of 10
http://www.translational-medicine.com/content/10/1/143between levels of HbA1c and the migratory (VEGF: p
< 0.001, r =−0.8 SDF-1: p< 0.001, r =−0.8) and colony
forming capacities (CFU-E: p = 0.001, r =−0.7, CFU-GM:
p = 0.001, r =−0.6) of BM-CPCs. (Figure 3. A, 3B, 4A
and 4B) The functional activity of BM-CPCs was signifi-
cantly reduced in DM patients with HbA1c >7% (n = 20)
as compared to DM patients with HbA1c <7% (n = 20).
(VEGF: p< 0.001, SDF-1: p< 0.001; CFU-E: p< 0.001,
CFU-GM: p< 0.001) (Figure 5A and 5B)
Discussion
In this study we examined the influence of the number
of diseased coronary arteries on the functional activity of
BM-CPCs in patients with IHD.
Coronary artery disease results from a chronic inflam-
matory disease of the vascular wall and leads to vessel
occlusion and organ damage. [17,18] Despite intenseefforts to determine the pathogenesis of atherosclerosis,
this process remains poorly understood. Reports suggest
that risk factors and a genetic predisposition together in-
duce inflammatory processes that lead to cell damage
and impair regeneration within the vessel wall. [19,20]
Since resident endothelial cells infrequently proliferate,
[21] it has been postulated that there are other sources
of vascular replenishment in response to continuous
damage [22]. Circulating progenitor cells derived from
bone marrow circulate in the peripheral blood and have
been implicated in neoangiogenesis after tissue ischemia
has occurred. [23-26] BM-CPCs is another population of
progenitor cells that has also been shown to have thera-
peutic potential in the pool of progenitor cells circulat-
ing within the blood. BM-CPCs are capable of
proliferating and differentiating into endothelial cells
and are therefore ideal candidates for vascular
Figure 3 A and B: The migratory response to VEGF and SDF-1 correlates inverse to the level of HbA1c in patients with DM.
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suggest that the systemic application or mobilization of
stem cells and progenitor cells beneficially influences the
repair of endothelial cells after injury and the progres-
sion of atherosclerosis. [29-35] Previous studies demon-
strate that risk factors for coronary artery disease
correlate with number and functional activity of BM-
CPCs. [8] Not only is the quantity of BM-CPCs altered,
but their function is also modified by ischemic condi-
tions and therapeutic interventions. [16] Migration is es-
sential for the stem/progenitor cells to invade the
ischemic tissue. SDF-1 and VEGF are both profoundly
upregulated in hypoxic tissue [36,37] and thus represent
physiologically relevant chemoattractants for the recruit-
ment of circulating progenitor cells to sites of ischemia.
Indeed, intramuscular injection of the chemoattractant
chemokine SDF-1 has recently been shown to increase
the number of incorporated BM-CPCs and to improve
neovascularization in vivo. [38] Thus, the migratory re-
sponse toward SDF-1 may indeed play a crucial role forintegration of BM-CPCs in ischemic tissue. In addition,
the accumulation of cardiovascular risk factors or an
increased overall risk is associated with impaired colony
forming activity of CPCs in healthy men. [9] Werner
et al. [18] identified a significant association between in-
creasing numbers and functional activities of BM-CPCs
and decreased risk of major cardiovascular event and
hospitalization in patients with coronary artery disease.
In humans, a small-scale study suggests that there is a
higher incidence of restenosis and revascularization in
patients with reduced levels of BM-CPCs than in
patients with increased numbers. [18,39] Recently we
showed that Intracoronary transplantation of autologous
BMCs may enhance and prolong the mobilisation as well
as functional activity of BM-CPCs in PB in patients with
ischemic heart disease and this might increase the re-
generative potency in IHD. [40-42] Moreover, the
mobilization of CD34+ and CD133+ BM-CPCs is further
impaired by DM in patients with IHD. [43,44] However,
it is unknown whether the functional activity of BM-
Figure 4 A and B: The colony forming capacitiy correlates inverse to the level of HbA1c in patients with DM.
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teries in patients with IHD. We demonstrated in our
study, that the functional activity of BM-CPCs was sig-
nificantly impaired in patients with IHD3 compared to
IHD2 and IHD1. Diabetes mellitus is associated with
both an increased risk of atherosclerotic disease and
poor outcome after vascular occlusion. The clinical se-
verity of vascular occlusive disease in diabetics has in
part been attributed to impaired collateral vessel devel-
opment [45]. Extensive studies have shown that the
numbers of circulating angiogenic cells are significantly
lower in type II diabetes, and their angiogenic potential
is also dramatically diminished. These cells display de-
fective adhesion to the endothelium, reduced prolifera-
tion rate, and impaired ability to create new vascular
structures. [11,12,46] On the basis of these findings, it is
tempting to speculate that the decrease of functional ac-
tivity of BM-CPCs by DM leads to progression of ath-
erosclerosis and increases the number of diseased
coronary arteries in patients with IHD. In line with this
hypothesis we observed in our study a significant higher
incidence of DM in patients with IHD3 compared to
IHD2 and IHD1. Furthermore, we demonstrated thatthe functional activity of BM-CPCs inversely correlated
with the level of HbA1c in IHD patients with DM. The
functional activity of BM-CPCs in DM patients with
HbA1c> 7% was significantly reduced compared to DM
patients with HbA1c <7%. Recent studies have shown
that the PPARϒ agonist pioglitazone treatment increases
the number and function of BM-CPCs in type 2 DM
patients with coronary artery disease. [47,48] Improved
levels of HbA1c by pharmacological therapy may lead to
increase of BM-CPCs mobilization and functional activ-
ity and thereby may enhance the vascular regeneration
in IHD patients with DM.
Conclusion
In the present study we could demonstrate that the
functional activity of BM-CPCs was impaired in patients
with IHD. This impairment correlates with increase of
the number of diseased coronary arteries. Moreover, the
regenerative capacity in ischemic tissue of BM-CPCs fur-
ther declines in IHD patients with DM.
Competing interests
The authors have no competing interests to declare.
Figure 5 A and B: The migration and colony forming capacities of BM-CPCs are significantly reduced in patients with HbA1c >7%
compared to patients with HbA1c <7%.
Bozdag-Turan et al. Journal of Translational Medicine 2012, 10:143 Page 8 of 10
http://www.translational-medicine.com/content/10/1/143Acknowledgements
We thank Andrea Thesenvitz for the technical assistance.
Author details
1Department of Internal Medicine, Division of Cardiology, University hospital
Rostock, Ernst Heydemann Str 6, Rostock 18055, Germany. 2Stem Cell
Institute, Ankara University, Ankara, Turkey.
Authors’ contributions
All authors have read and approved the final manuscript. The specific
contributions of each author are; IBT, RGT and CAN conceived, designed and
directed the entire study, interpreted all data and wrote the manuscript. LP,
NA, CHT, IA, SK, JO, HS, SL, TH, SD, RA, HI and GA collected the preliminary
data, participated in the study design, interpretation of the data, revision of
paper.
Received: 8 March 2012 Accepted: 9 July 2012
Published: 9 July 2012
References
1. Luttun A, Carmeliet G, Carmeliet P: Vascular progenitors: from biology to
treatment. Trends Cardiovasc Med 2002, 12:88–96.
2. Szmitko PE, Fedak PW, Weisel RD, Stewart DJ, Kutryk MJ, Verma S:
Endothelial progenitor cells, new hope for a broken heart. Circulation
2003, 107:3093–3100.
3. Deschaseaux F, Pontikoglou C, Sensébé L: Bone regeneration: the stem/
progenitor cells point of view. J Cell Mol Med 2010, 14:103–115.
4. Timmermans F, Plum J, Yöder MC, Ingram DA, Vandekerckhove B, Case J:
Endothelial progenitor cells: identity defined? J Cell Mol Med 2010, 13:87–
102.5. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M,
Magner M, Isner JM: Bone marrow origin of endothelial progenitor cells
responsible for postnatal vasculogenesis in physiological and
pathological neovascularization. Circ Res 1999, 85:221–228.
6. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M,
Isner JM, Asahara T: Ischemia-and cytokine-induced mobilization of bone-
marrow-derived endothelial progenitor cells for neovascularization. Nat
Med 1999, 5:434–438.
7. Hattori K, Heissig B, Tashiro K, Honjo T, Tateno M, Shieh JH, Hackett NR,
Quitoriano MS, Crystal RG, Rafii S, Moore MA: Plasma elevation of
stromal cell-derived factor-1 induces mobilization of mature and
immature hematopoetic progenitor and stem cells. Blood 2001,
97:3354–3360.
8. Moore MA, Hattori K, Heissig B, Shieh JH, Dias S, Crystal RG, Rafii S:
Mobilization of endothelial and hematopoietic stem and progenitor cells
by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and
aniopoietin. Ann NY Acad Sci. 2001, 938:36–47.
9. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel
T: Circulating endothelial progenitor cells, vascular function, and
cardiovascular risk. N Engl J Med 2003, 348:593–600.
10. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM,
Dimmeler S: Number and migratory activity of circulating endothelial
progenitor cells inversely correlate with risk factors for coronary artery
disease. Circ Res 2001, 89:E1–E7.
11. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine
JP, Gurtner GC: Human endothelial progenitor cells from type II diabetics
exhibit impaired proliferation, adhesion, and incorporation into vascular
structures. Circulation 2002, 106:2781–2786.
12. Fadini GP, Sartore S, Albiero M, Baesso I, Murphy E, Menegolo M, Grego F,
de Kreutzenberg Vigili S, Tiengo A, Agostini C, Avogaro A: Number and
Bozdag-Turan et al. Journal of Translational Medicine 2012, 10:143 Page 9 of 10
http://www.translational-medicine.com/content/10/1/143function of endothelial progenitor cells as a marker of severity for
diabetic vasculopathy. Arterioscler Thromb Vasc Biol 2006, 26:2140–2146.
13. Li M, Takeneka H, Asai J, Ibusuki K, Mizukami Y, Maruyama K, Yoon YS,
Wecker A, Luedemann C, Eaton E, Silver M, Thorne T, Losordo DW:
Endothelial progenitor thrombospondin-1 mediates diabetes induced
delay in reendothelialization following arterial injury. Circ Res 2006,
98:697–704.
14. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC,
Vekshtein VI, Selwyn AP, Ganz P: Coronary vasomotor response to
acetylcholine relates to risk factors for coronary artery disease. Circulation
1990, 81:491–497.
15. Scanlon PJ, Faxon DP, Audet AM, Carabello B, Dehmer GJ, Eagle KA, Legako
RD, Leon DF, Murray JA, Nissen SE, Pepine CJ, Watson RM, Ritchie JL,
Gibbons RJ, Cheitlin MD, Gardner TJ, Garson A Jr, Russell RO Jr, Ryan TJ,
Smith SC Jr: ACC/AHA guidelines for coronary angiography: a report of
the American College of Cardiology/American Heart Association Task
Force on practice guidelines (Committee on Coronary Angiography):
developed in collaboration with the Society for Cardiac Angiography
and Interventions. J Am Coll Cardiol 1999, 33:1756–1824.
16. Heeschen C, Lehman R, Honold J, Assmus B, Aicher A, Walter DH, Martin H,
Zeiher AM, Dimmeler S: Profoundly reduced neovascularization capacity
of bone marrow mononuclear cells derived from patients with chronic
ischemic heart disease. Circulation 2004, 109:1615–1622.
17. Ross R: Atherosclerosis an inflammatory disease. N Engl J Med 1999,
340:115–126.
18. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Böhm M, Nickenig
G: Circulating Endothelial Progenitor Cells and Cardiovascular Outcomes.
N Engl J Med 2005, 353:999–1007.
19. Choy JC, Granville DJ, Hunt DW, McManus BM: Endothelial cell apoptosis:
biochemical characteristics and potential implications for atherosclerosis.
J Mol Cell Cardiol 2001, 33:1673–1690.
20. Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, Girardi L, Yurt R, Himel H,
Rafii S: Vascular trauma induces rapid but transient mobilization of VEGFR2
(+) AC133(+) endothelial precursor cells. Circ Res 2001, 88:167–174.
21. Schwartz SM, Benditt EP: Clustering of replicating cells in aortic
endothelium. Proc Natl Acad Sci U S A 1976, 73:651–653.
22. Opden Buijs J, Musters M, Verrips T, Post JA, Braam B, van Riel N:
Mathematical modeling of vascular endothelial layer maintenance: the
role of endothelial cell division, progenitor cell homing, and telomere
shortening. Am J Physiol Heart Circ Physiol 2004, 287:H2651–H2658.
23. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T,
Witzenbichler B, Schatteman G, Isner JM: Isolation of putative progenitor
endothelial cells for angiogenesis. Science 1997, 275:964–967.
24. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T,
Isner JM, Asahara T: Transplantation of ex vivo expanded endothelial
progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S
A 2000, 97:3422–3427.
25. Kawamoto A, Gwon HC, Iwaguro H, Yamaguchi JI, Uchida S, Masuda H,
Silver M, Ma H, Kearney M, Isner JM, Asahara T: Therapeutic potential of
ex vivo expanded endothelial progenitor cells for myocardial ischemia.
Circulation 2001, 103:634–637.
26. Rafii S, Lyden D: Therapeutic stem and progenitor cell transplantation for
organ vascularization and regeneration. Nat Med 2003, 9:702–712.
27. Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M, Schuch
G, Schafhausen P, Mende T, Kilic N, Kluge K, Schäfer B, Hossfeld DK, Fiedler
W: In vitro differentiation of endothelial cells from AC133-positive
progenitor cells. Blood 2000, 95:3106–3112.
28. Gunsilius E, Duba HC, Petzer AL, Kähler CM, Gastl GA: Contribution of
endothelial cells of hematopoietic origin to blood vessel formation. Circ
Res 2001, 88:E1.
29. Kong D, Melo LG, Gnecchi M, Zhang L, Mostoslavsky G, Liew CC, Pratt RE,
Dzau VJ: Cytokine-induced mobilization of circulating endothelial
progenitor cells enhances repair of injured arteries. Circulation 2004,
110:2039–2046.
30. Nowak G, Karrar A, Holmen C, Nava S, Uzunel M, Hultenby K, Sumitran-
Holgersson S: Expression of vascular endothelial growth factor receptor-2
or tie-2 on peripheral blood cells defines functionally competent cell
populations capable of reendothelialization. Circulation 2004, 110:3699–
3707.
31. Strehlow K, Werner N, Berweiler J, Link A, Dirnagl U, Priller J, Laufs K, Ghaeni
L, Milosevic M, Böhm M, Nickenig G: Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes
neointima formation. Circulation 2003, 107:3059–3065.
32. Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T,
Nishimura H, Losordo DW, Asahara T, Isner JM: Statin therapy accelerates
reendothelialization: a novel effect involving mobilization and
incorporation of bone marrow-derived endothelial progenitor cells.
Circulation 2002, 105:3017–3024.
33. Werner N, Priller J, Laufs U, Endres M, Böhm M, Dirnagl U, Nickenig G: Bone
marrow-derived progenitor cells modulate vascular reendothelialization
and neointimal formation: effect of 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibition. Arterioscler Thromb Vasc Biol 2002,
22:1567–1572.
34. Werner N, Junk S, Laufs U, Link A, Walenta K, Bohm M, Nickenig G:
Intravenous transfusion of endothelial progenitor cells reduces
neointima formation after vascular injury. Circ Res 2003, 93:e17–e24.
35. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, Wang T, Gregg D,
Ramaswami P, Pippen AM, Annex BH, Dong C, Taylor DA: Aging,
progenitor cell exhaustion, and atherosclerosis. Circulation 2003, 108:457–
463.
36. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA:
Early expression of angiogenesis factors in acute myocardial ischemia
and infarction. N Eng J Med 2000, 342:626–633.
37. Pilarisetti K, Gupta SK: Cloning and relative expression analysis of rat
stromal cell derived factor-1 (SDF-1) 1:SDF-1 alpha mRNA is selectively
induced in rat model of myocardial infarction. Inflammation 2001, 25:293–
300.
38. Yamaguchi J, Kussano KF, Masuo O, Kawamoto A, Silver M, Murasawa S,
Bosch-Marce M, Masuda H, Losordo DW, Isner JM, Asahara T: Stromal cell-
derived factor-1 effects on ex vivo expanded endothelial progenitor cell
recruitment for ischemic neovascularization. Circulation 2003, 107:1322–
1328.
39. George J, Herz I, Goldstein E, Abashidze S, Deutch V, Finkelstein A,
Michowitz Y, Miller H, Keren G: Number and adhesive properties of
circulating endothelial progenitor cells in patients with in-stent
restenosis. Arterioscler Thromb Vasc Biol 2003, 23:e57–e60.
40. Turan RG, Bozdag-Turan I, Ortak J, Akin I, Kische S, Schneider H, Turan
CH, Rehders TC, Rauchhaus M, Kleinfeldt T, Adolph E, Brehm M, Yokus S,
Steiner S, Sahin K, Nienaber CA, Ince H: Improved mobilisation of the
CD34+ and CD133+ bone marrow derived circulating progenitor cells
by freshly isolated intracoronary bone marrow cells transplantation in
patients with ischemic heart disease. Stem Cell and Dev 2011, 20
(9):1491–1501.
41. Turan RG, Bozdag-Turan I, Ortak J, Kische S, Akin I, Schneider H, Turan CH,
Rehders TC, Rauchhaus M, Kleinfeldt T, Belu C, Brehm M, Yokus S, Steiner S,
Sahin K, Nienaber CA, Ince H: Improved functional activity of bone
marrow derived circulating progenitor cells after intra coronary freshly
isolated bone marrow cells transplantation in patients with ischemic
heart disease. Stem Cell Rev 2011, 7(3):646–656.
42. Turan RG, Bozdag-Turan I, Turan CH, Ortak J, Akin I, Kische S, Schneider H,
Rauchhaus M, Rehders TC, Kleinfeldt T, Belu C, Amen S, Hermann T, Yokus S,
Brehm M, Steiner S, Chatterjee T, Sahin K, Nienaber CA, Ince H: Enhanced
mobilisation of the bone marrow derived circulating progenitor cells by
intracoronary freshly isolated bone marrow cells transplantation in
patients with acute myocardial infarction. J Cell Mol Med 2012, 16(4):852–
864.
43. Turan RG, Turan CH, Bozdag-Turan I, Ortak J, Akin I, Kische S, Schneider H,
Kleinfeldt T, Rehders TC, Rauchhaus M, Adolph E, Amen S, Hermann T,
Yokus S, Brehm M, Steiner S, Sahin K, Nienaber CA, Ince H: Impaired
Mobilization of CD133(+) Bone Marrow-Derived Circulating Progenitor
Cells With an Increased Number of Diseased Coronary Arteries in
Ischemic Heart Disease Patients With Diabetes. Circ J 2011, 75(11):2635–
2641.
44. Bozdag-Turan I, Turan RG, Turan CH, Ludovicy S, Akin I, Kische S, Arsoy NS,
Schneider H, Ortak J, Rehders T, Hermann T, Paranskaya L, Kohlschein P,
Bastian M, Ulus AT, Sahin K, Ince H, Nienaber CA: Relation between the
frequency of CD34+ bone marrow derived circulating progenitor cells
and the number of diseased coronary arteries in patients with
myocardial ischemia and diabetes. Cardiovasc Diabetol 2011, 10:107.
45. Abaci A, Oguzhan A, Kahraman S, Eryol NK, Unal S, Arinç H, Ergin A: Effect
of diabetes mellitus on formation of coronary collateral vessels.
Circulation 1999, 99:2239–2242.
Bozdag-Turan et al. Journal of Translational Medicine 2012, 10:143 Page 10 of 10
http://www.translational-medicine.com/content/10/1/14346. Caballero S, Sengupta N, Afzal A, Chang KH, Li Calzi S, Guberski DL, Kern TS,
Grant MB: Ischemic vascular damage can be repaired by healthy, but not
diabetic, endothelial progenitor cells. Diabetes J 2007, 56:960–967.
47. Werner C, Kamani CH, Gensch C, Böhm M, Laufs U: The peroxisome
proliferator-activated receptor-y agonist pioglitazone increases number
and function of endothelial progenitor cells in patients with Coronary
Artery Disease and normal glucose tolerance. Diabetes J 2007, 56:2609–
2615.
48. Makino H, Okada S, Nagumo A, Sugisawa T, Miyamoto Y, Kishimoto I, Akie
TK, Soma T, Taguchi A, Yoshimasa Y: Pioglitazone treatment stimulates
circulating CD34-positive cells in type 2 diabetes patients. Diabetes Res
Clin Pract 2008, 81:327–330.
doi:10.1186/1479-5876-10-143
Cite this article as: Bozdag-Turan et al.: Correlation between the
functional impairment of bone marrow-derived circulating progenitor
cells and the extend of coronary artery disease. Journal of Translational
Medicine 2012 10:143.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
